Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist

Objective: This study evaluated the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of eneboparatide (AZP-3601), a novel agonist of the PTH receptor 1 developed for the treatment of hypoparathyroidism. Design: This was a randomized, double-blind, placebo-controlled study. One-h...

Descrición completa

Detalles Bibliográficos

Principais autores:	Michel Ovize, Soraya Allas, Michael D Culler, Stephane Milano, Taha Ouldrouis, Mark Sumeray, Jeroen van de Wetering de Rooij, Michael Mannstadt
Formato:	Artigo
Idioma:	Inglês
Publicado:	Bioscientifica 2025-06-01
Series:	Endocrine Connections
Assuntos:	hypoparathyroidism parathormone calcium kidney bone
Acceso en liña:	https://ec.bioscientifica.com/view/journals/ec/14/6/EC-24-0464.xml
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!